Mo1610: IMPACT OF ELAFIBRANOR ON MARKERS OF DISEASE ACTIVITY AND PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CHOLANGITIS

Kris V. Kowdley; Christopher L. Bowlus; Marlyn J. Mayo; John M. Vierling; Ira Jacobson; Nuno Antunes; Marwan Sleiman; Nathan Touati; Claudia O. Zein; Cynthia Levy

doi:10.1016/S0016-5085(25)05043-7

Back

Mo1610: IMPACT OF ELAFIBRANOR ON MARKERS OF DISEASE ACTIVITY AND PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CHOLANGITIS

Journal article

Peer reviewed

Mo1610: IMPACT OF ELAFIBRANOR ON MARKERS OF DISEASE ACTIVITY AND PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CHOLANGITIS

Kris V. Kowdley, Christopher L. Bowlus, Marlyn J. Mayo, John M. Vierling, Ira Jacobson, Nuno Antunes, Marwan Sleiman, Nathan Touati, Claudia O. Zein and Cynthia Levy

Gastroenterology (New York, N.Y. 1943), Vol.169(1), p.S-1814

2025-05

DOI: https://doi.org/10.1016/S0016-5085(25)05043-7

Appears in Miller School of Medicine - Latest Publications

Metrics

1 Record Views

Details

Title: Mo1610: IMPACT OF ELAFIBRANOR ON MARKERS OF DISEASE ACTIVITY AND PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CHOLANGITIS
Creators: Kris V. Kowdley
Christopher L. Bowlus
Marlyn J. Mayo
John M. Vierling
Ira Jacobson
Nuno Antunes
Marwan Sleiman
Nathan Touati
Claudia O. Zein
Cynthia Levy
Publication Details: Gastroenterology (New York, N.Y. 1943), Vol.169(1), p.S-1814
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hepatology
Language: English
Resource Type: Journal article
Record Identifier: 991032730221602976